title: A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer.
abstract: Recent studies have shown the combination of C-reactive protein (CRP) and albumin (The modified Glasgow Prognostic Score, mGPS) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 460 consecutive SCLC patients were screened. Eligible patient was assigned a mGPS of 0, 1, or 2 based on pre-treatment plasma CRP and albumin (0: CRP ≤ 10 mg/L; 1: CRP >10 mg/L and albumin ≥ 35 g/L; 2: CRP > 10 mg/L and albumin < 35 g/L). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors for SCLC. A total of 359 patients were analyzed. The mGPS of 0, 1, and 2 was assigned to 66.3, 30.6, and 3.1 % of total patients. For patients with mGPS of 0, 1, and 2, median overall survival (OS) was 30.4, 28.2, and 14.3 months, respectively (P < 0.001). Performance status (P < 0.001), disease stage (P < 0.001) and pre-treatment LDH (P < 0.001) also significantly predicted OS. Multivariate analyses showed mGPS was an independent prognostic factor (P < 0.001). This study demonstrated that higher mGPS independently predicts worse OS for SCLC patients. The assessment of mGPS could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.
authors.affiliation: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651# Dongfeng East Road, Guangzhou, China, 510060.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.forename: Shaodong
authors.initials: S
authors.lastname: Hong
authors.forename: Zhihuang
authors.initials: Z
authors.lastname: Hu
authors.forename: Xue
authors.initials: X
authors.lastname: Hou
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
authors.forename: Hongyun
authors.initials: H
authors.lastname: Zhao
authors.forename: Wenhua
authors.initials: W
authors.lastname: Liang
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Wenfeng
authors.initials: W
authors.lastname: Fang
authors.forename: Xuan
authors.initials: X
authors.lastname: Wu
authors.forename: Tao
authors.initials: T
authors.lastname: Qin
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality; D055815:Young Adult